Q-omics provides the consensus-scored HSPB2-C11orf52 profile across patient tissues and cancer cell-line models. HSPB2-C11orf52 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, HSPB2-C11orf52 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, HSPB2-C11orf52 RNA expression shows 8,500 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SKCM, BLCA, and THYM as cancer lineages where HSPB2-C11orf52 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSPB2-C11orf52 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSPB2-C11orf52 survival associations across molecular data types. HSPB2-C11orf52 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSPB2-C11orf52 RNA expression–survival associations across cancer types. High HSPB2-C11orf52 expression shows unfavorable associations in KICH and ACC, but favorable associations in SKCM, UCS, KIRP and MESO. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for HSPB2-C11orf52 RNA expression.
This table summarizes HSPB2-C11orf52 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for HSPB2-C11orf52. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSPB2-C11orf52 shows lower tumor expression in BLCA, THCA, KICH, BRCA, UCEC and LUSC. The BLCA box plot shows higher HSPB2-C11orf52 RNA expression in normal versus tumor tissue (log2 FC = −0.120, t-test p < 0.001).
This table shows molecular features associated with HSPB2-C11orf52 in patient tissues and cancer cell lines. In patient samples, HSPB2-C11orf52 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
